These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18683789)

  • 1. [How to overcome the obstacles in the adoptive immunotherapy for leukemia].
    Pan JX; Chen ZZ
    Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):91-2. PubMed ID: 18683789
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine therapy and adoptive immunotherapy in hematologic malignancies.
    Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):373-4. PubMed ID: 18790443
    [No Abstract]   [Full Text] [Related]  

  • 4. An easy way to make a good anti-tumor chimeric antigen receptor T cell?
    Muranski P
    Cytotherapy; 2014 May; 16(5):577-8. PubMed ID: 24725890
    [No Abstract]   [Full Text] [Related]  

  • 5. On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies.
    Dellabona P; Casorati G; de Lalla C; Montagna D; Locatelli F
    Clin Immunol; 2011 Aug; 140(2):152-9. PubMed ID: 21185785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Principal and perspective of adoptive immuno-cell therapy for hematological malignancies].
    Akatsuka Y
    Rinsho Ketsueki; 2007 Oct; 48(10):1328-38. PubMed ID: 17933117
    [No Abstract]   [Full Text] [Related]  

  • 7. [The HIV virus used as antileukemic vector].
    Nau JY
    Rev Med Suisse; 2013 Jan; 9(368):86-7. PubMed ID: 23367714
    [No Abstract]   [Full Text] [Related]  

  • 8. Chimerism-directed adoptive immunotherapy in prevention and treatment of post-transplant relapse of leukemia in childhood.
    Formánková R; Sedlácek P; Krsková L; Ríhová H; Srámková L; Star J;
    Haematologica; 2003 Jan; 88(1):117-8. PubMed ID: 12551838
    [No Abstract]   [Full Text] [Related]  

  • 9. First person: Hagop Kantarjian, MD: MD Anderson physician reflects on decades of leading research into new leukemia drugs.
    Printz C
    Cancer; 2018 Jun; 124(12):2469. PubMed ID: 29873825
    [No Abstract]   [Full Text] [Related]  

  • 10. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.
    Introna M; Pievani A; Borleri G; Capelli C; Algarotti A; Micò C; Grassi A; Oldani E; Golay J; Rambaldi A
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1603-7. PubMed ID: 20685246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay.
    Jedema I; Meij P; Steeneveld E; Hoogendoorn M; Nijmeijer BA; van de Meent M; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):636-43. PubMed ID: 17255287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
    Falkenburg JH; Willemze R
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation.
    Locatelli F; Comoli P; Montagna D; Rossi F; Daudt L; Maccario R
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):479-92. PubMed ID: 15498718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy.
    Res Initiat Treat Action; 1999 Jan; 5(1):19. PubMed ID: 11366227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic function of umbilical cord blood natural killer cells: relevance to adoptive immunotherapy.
    Lin SJ; Kuo ML
    Pediatr Hematol Oncol; 2011 Nov; 28(8):640-6. PubMed ID: 21970456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.
    Stern M; Passweg JR; Meyer-Monard S; Esser R; Tonn T; Soerensen J; Paulussen M; Gratwohl A; Klingebiel T; Bader P; Tichelli A; Schwabe D; Koehl U
    Bone Marrow Transplant; 2013 Mar; 48(3):433-8. PubMed ID: 22941380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy in human and canine chimeras--the role of interferon alfa. EBMT Chronic Leukemia Working Party.
    Kolb HJ; Mittermüller J; Hertenstein H; Schumm M; Holler E; de Witte T; Günther W; Ljungman P; Goldman JM
    Semin Hematol; 1993 Jul; 30(3 Suppl 3):37-9. PubMed ID: 8235705
    [No Abstract]   [Full Text] [Related]  

  • 18. Adoptive immunotherapy poised to deliver on decades-old promise.
    Hede K
    J Natl Cancer Inst; 2012 Jan; 104(2):88-90. PubMed ID: 22215852
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.
    Porter DL; Hexner EO; Cooley S; Miller JS
    Cancer Treat Res; 2009; 144():497-537. PubMed ID: 19779876
    [No Abstract]   [Full Text] [Related]  

  • 20. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
    Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
    Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.